Skip to content

The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study

The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06517628
Acronym
HOPE
Enrollment
1000
Registered
2024-07-24
Start date
2025-01-14
Completion date
2028-06-30
Last updated
2025-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Complications, Cardiovascular

Keywords

Pregnancy, cardio-obstetrics, Structures of Care, Quality of Care, Disparities, Heart disease in pregnancy, Pregnancy complications, Adverse pregnancy outcomes, Major adverse cardiac events, Neonatal adverse events, Quality of life

Brief summary

This is a prospective, observational study which is evaluating the obstetrical, neonatal, and cardiovascular outcomes of 1000 pregnant people with known heart disease to define how best to structure cardio-obstetrics care to optimize outcomes.

Detailed description

The US is the only industrialized nation to experience a rise in maternal mortality over the last decade. Despite the Healthy People 2030 agenda target of reducing maternal mortality by 10%, rates in the United States are predicted to increase. Furthermore, maternal mortality disproportionately impacts Black, Hispanic, American Indian/Alaskan Native (AIAN), and Asian/Pacific Islander birthing people, who die at a rate that far greater than their White counterparts. Black birthing people are twice as likely to experience severe maternal morbidity (SMM) and 3-4X more likely to die, even after adjusting for demographic and hospital factors. Unfortunately, this gap is widening, with a 20% increase in death for Blacks as compared with a 5% rise in Whites over the last decade. Understanding contributors to adverse outcomes for marginalized birthing populations cannot solely be determined from retrospective chart adjudication and requires prospective evaluation to better understand patient and treatment factors contributing to maternal morbidity and mortality. Despite affecting only 2-4% of pregnancies, cardiovascular disease (CVD) accounts for \>30% of maternal deaths, making it a leading cause of maternal mortality for all birthing people and the number one cause in the Black population. Pregnant people with acquired and congenital heart disease experience the majority of CV-related morbidity and mortality, of which over three quarters have been deemed preventable. The prevalence of CVD is expected to grow as risk factors for CV-related death (obesity, advanced maternal age, hypertensive disorders, and preexisting heart disease) are rising dramatically in pregnant people, which disproportionately burdens marginalized populations. Provider-based factors are a leading cause of preventable morbidity, yet the lack of evidence-based guidelines, means of risk-stratifying pregnant people with CVD, or insight into how best to structure care limits the ability to improve maternal outcomes. Mortality is not the only important outcome for pregnant people with CVD. For every maternal death, it is estimated that 100 people - 50,000 per year - will suffer severe maternal morbidity (SMM) during delivery, with significant costs to both their families and the economy. Adverse pregnancy outcomes (APOs) and neonatal adverse clinical events (NACEs), including pre-eclampsia, preterm delivery, fetal growth restriction, stillbirth and maternal hemorrhage, are all significantly more common in those with heart disease. Pregnant people who survive these events are more likely to suffer post-traumatic stress and depression, which can adversely impact mother-child bonding and long-term health. Importantly, there are no studies in this population evaluating quality of life, which cannot be measured using retrospective data. To address the critical need for reversing the US trend in maternal morbidity and mortality, the Heart Outcomes in Pregnancy Expectations (HOPE) study will focus on the highest risk population, pregnant people with CVD. It will provide deeper insights into maternal risk factors, their association with care, and the influence of alternative structures of cardio-obstetric care with APO, MACE, and NACE outcomes. It is a multi-site, multidisciplinary prospective study at \>30 cardio-obstetrics clinics throughout the US with a key secondary goal of better understanding racial disparities in care and outcomes. Not only will traditional APOs, MACE, and NACE events from presentation to 1-year after delivery be collected, generic and disease-specific quality of life will be measured as a way to evaluate their independent impact on outcomes. Preliminary insights through our pilot program highlight the importance of better structures of care as a means of improving outcomes, which has previously been established in other clinical settings, but not in cardio-obstetrics care. The investigators have identified 6 key structures of care that have been variably adopted through the US and for which additional data to define their independent association with outcomes is needed. These include: 1. multidisciplinary (OB/maternal-fetal medicine \[MFM\], cardiology, anesthesia, critical care, etc.) care teams; 2. a COB care coordinator; 3. coordinated inter-disciplinary patient evaluation; 4. team debriefing 5. the ability to perform high-risk deliveries in the ICU and 6. formalized warm hand offs to primary or sub-specialty care after delivery. After adjusting for extensive patient factors associated with adverse outcomes, the independent association of these structures of care with outcomes will be estimated as a foundation for testing and disseminating those that are most effective.

Interventions

OTHERPurely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.

The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.

Sponsors

Albert Einstein College of Medicine
CollaboratorOTHER
Baylor College of Medicine
CollaboratorOTHER
Beth Israel Deaconess Medical Center, Inc.
CollaboratorUNKNOWN
The Children's Hospital Corporation
CollaboratorUNKNOWN
The Brigham and Women's Hospital, Inc.
CollaboratorUNKNOWN
The Trustees of Columbia University in the City of New York
CollaboratorUNKNOWN
Henry Ford Hospital
CollaboratorOTHER
The Johns Hopkins University
CollaboratorUNKNOWN
The Miriam Hospital/Lifespan
CollaboratorUNKNOWN
The General Hospital Corporation d/b/a Massachusetts General Hospital
CollaboratorUNKNOWN
Northwell Health
CollaboratorOTHER
Northwestern University
CollaboratorOTHER
Oregon Health and Science University
CollaboratorOTHER
Saint Luke's Health System Inc.
CollaboratorUNKNOWN
Board of Trustees of the Leland Stanford Junior University
CollaboratorUNKNOWN
The Research Foundation for the State University of New York
CollaboratorUNKNOWN
The Regents of the University of California, Irvine
CollaboratorUNKNOWN
The Regents of the University of California, Los Angeles
CollaboratorUNKNOWN
University of North Carolina, Chapel Hill
CollaboratorOTHER
The Board of Trustees of the University of Illinois
CollaboratorUNKNOWN
Trustees of Indiana University
CollaboratorUNKNOWN
University of Kansas Medical Center
CollaboratorOTHER
University of Massachusetts Chan Medical School
CollaboratorUNKNOWN
Regents of the University of Michigan
CollaboratorUNKNOWN
University of Mississippi Medical Center
CollaboratorOTHER
The Curators of the University of Missouri
CollaboratorUNKNOWN
The Trustees of the University of Pennsylvania
CollaboratorUNKNOWN
University of Pittsburgh
CollaboratorOTHER
The University of South Florida Board of Trustees for University of South Florida
CollaboratorUNKNOWN
University of Washington
CollaboratorOTHER
University of Texas Southwestern Medical Center
CollaboratorOTHER
Weil Medical Colleqe of Cornell University
CollaboratorUNKNOWN
Women and Infants Hospital of Rhode Island
CollaboratorOTHER
Tennessee Maternal Fetal Medicine PLC
CollaboratorUNKNOWN
University of Missouri, Kansas City
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion: Must have one or more condition(s) within the 6 following categories - Repaired or Unrepaired * Congenital or structural heart disease * Aortopathies * Arrhythmias * Cardiomyopathies and Heart Failure * Coronary disease * Other (Current endocarditis or history of endocarditis, Pericarditis, Pericardial effusion - Moderate or Large, Pericardial constriction, Pulmonary hypertension (all types) defined as mean pulmonary artery systolic pressure of \>20 mmHg by right heart catheterization or pulmonary hypertension estimated in the severe range by echo)

Exclusion criteria

* Unable to participate in telephone follow-up * Too hard of hearing to do follow-up by telephone or deaf * Incarcerated prisoner * History of dementia. * Subjects without a way for contact by telephone for follow-up * Refused participation in the study * Unable to consent for self * Traumatic Aortic Disease * Peripartum cardiomyopathy diagnosed in current pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Rate of Adverse pregnancy outcomesup to 6 weeks postpartumHELLP, preeclampsia, gestational hypertension, eclampsia, superimposed preeclampsia on chronic hypertension (SIPE), premature preterm rupture of membranes (PPROM), preterm delivery, thrombotic complications, hemorrhage, maternal mortality, placental abruption, Admission ICU delivery

Secondary

MeasureTime frameDescription
Rate of Maternal Adverse Cardiac Events (MACE)Up to 1 year postpartumA composite outcome including any of the following: cardiovascular death, non-fatal stroke, myocardial infarction, hospitalization for acute coronary syndromes, urgent revascularization procedures, decompensated heart failure, aortic dissection, clinically significant arrhythmia requiring treatment (eg. atrial fibrillation/flutter, SVT, ventricular tachycardia, etc), cardiac transplant
Rate of Neonatal adverse clinical events (NACE)Through maternal hospital dischargeA composite outcome including any of the following: APGARS \< 8 at 5 minutes, birthweight of \< 2500 grams, NICU admission, supplemental oxygen use, neonatal death, fetal death, spontaneous abortion/miscarriage, intrauterine fetal growth restriction

Other

MeasureTime frameDescription
Perceived Discrimination will be assessed using the Experience of Depression ScaleEnrollment and 6 and 12 months after deliveryThis questionnaire will be completed on enrollment and at 6 and 12 months after delivery so that cross-sectional and changes over time through 1 year after delivery can be compared by patient characteristics and structures of care.
Self-perceived Health Status will be assessed using a version of the Kansas City Cardiomyopathy Questionnaire Modified for PregnancyEnrollment, 3rd Trimester, and 6 weeks, 6 months and 12 months after deliveryThis questionnaire will be completed on enrollment and changes over time through 1 year after delivery will be compared by patient characteristics and structures of care.
Changes in Generic Quality of Life as Assessed by the Short Form-36Through 1 year post partumAll patients will complete the Short Form-36 on enrollment and changes over time through 1 year after delivery and will be compared by patient characteristics and structures of care.
Atrial Fibrillation-specific Health Status over Time among Participants with a History of Atrial FibrillationEnrollment, 3rd Trimester, and 6 weeks and 12 months after deliveryThis questionnaire will be completed by participants with a history of atrial fibrillation on enrollment and changes over time through 1 year after delivery and will be compared by patient characteristics and structures of care.
Disease-specific Health Status over Time among Participants with a History of Congenital Heart DiseaseEnrollment, 3rd Trimester, and 6 weeks and 12 months after deliveryThis questionnaire will be completed by participants with a history of congenital heart disease on enrollment and changes over time through 1 year after delivery and will be compared by patient characteristics and structures of care.
Coronary-specific Health Status over Time among Participants with a History of Coronary DiseaseEnrollment, 3rd Trimester, and 6 weeks and 12 months after deliveryThis questionnaire will be completed by participants with a history of coronary artery disease (including SCAD) on enrollment and changes over time through 1 year after delivery and will be compared by patient characteristics and structures of care.
Changes in Depressive Symptoms, as Assessed by the Edinburgh Postpartum Depression ScaleThrough 1 year post partumThis questionnaire will be completed on enrollment and changes over time through 1 year after delivery and will be compared by patient characteristics and structures of care.
Experiences with pregnancy care and delivery will be assessed with the Childbirth Experience SurveyThird trimester and 6 weeks after deliveryThis questionnaire will be completed during the 3rd trimester and 6 weeks after delivery and will be compared by patient characteristics and structures of care.

Countries

United States

Contacts

Primary ContactKaren L Florio, DO, MPH
klwa42@umsystem.edu631-579-1030
Backup ContactAnna Grodzinsky, MD, MS
agrodzinsky@saint-lukes.org816-932-2000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026